CTIC CTI BioPharma Corp.

4.73
-0.01  -0.21%
Previous Close 4.74
Open 4.70
Price To book 7.42
Market Cap 132.44M
Shares 28,001,000
Volume 68,066
Short Ratio 1.72
Av. Daily Volume 795,277

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Top-line data from confirmatory trial required for full EMA approval due by end of 2017.
PIXUVRI
B-cell non-Hodgkin lymphoma
PERSIST-2 data released August 2016. One of two primary endpoints met. Announced January 5, 2017 removal of clinical hold. Additional trial to commence 2Q 2017.
Pacritinib
Myelofibrosis
Phase 3 trial potentially in the pipeline.
Tosedostat
Older patients with AML or high-risk myelodysplastic syndrome (MDS) - cancer
Phase 3 - noted July 2016 that unlikely to have survival benefit
OPAXIO
Ovarian cancer

Latest News

  1. CTI BIOPHARMA CORP Files SEC form 8-K, Other Events
  2. CTI BioPharma to Present at the BIO CEO & Investor Conference
  3. CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
  4. CTI BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
  5. CTI BioPharma Appoints Leading BioPharma Executive Michael Metzger To Board Of Directors
  6. CTI BIOPHARMA CORP Files SEC form 8-K, Other Events
  7. Latest Reports on Recent Market Movers: 3D Systems and CTI BioPharma
  8. CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
  9. CTI BioPharma Announces Progress Of Lead Programs And Strategic Objectives For 2017
  10. CTI Biopharma stock revived after FDA ruling, reverse stock split
  11. CTI BIOPHARMA CORP Files SEC form 8-K, Material Modification to Rights of Security Holders
  12. Why CTI BioPharma Corp. Stock Popped Today
  13. CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib
  14. ETFs with exposure to CTI BioPharma Corp. : January 4, 2017
  15. CTI BioPharma Corp. breached its 50 day moving average in a Bullish Manner : CTIC-US : January 4, 2017
  16. CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Finan
  17. CTI BIOPHARMA CORP Files SEC form 8-K, Material Modification to Rights of Security Holders
  18. ETFs with exposure to CTI BioPharma Corp. : December 13, 2016
  19. Do Hedge Funds Love Manning and Napier Inc (MN)?
  20. CTI BIOPHARMA CORP Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits